IP Library Granted Patent US 11,993,770
Granted Patent B2
US 11,993,770 · App. 18/526,745 · Granted May 28, 2024

Methods for targeted insertion of DNA in genes

Inventor: Nicholas J. Baltes (Oakdale, MN)
Assignee: BLUEALLELE CORPORATION
C12N15/102C12N15/907C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,993,770
App. No.
18/526,745
Granted
May 28, 2024
Kind
B2
Abstract

Methods and compositions for modifying the coding sequence of endogenous genes using rare-cutting endonucleases and transposases. The methods and compositions described herein can be used to modify the coding sequence of endogenous genes.

Claims (11)

1. A recombinant nucleic acid comprising,

(i) a transgene, the transgene comprising from 5′ to 3′ orientation:

a first splice acceptor, a first coding sequence, a first terminator, a second terminator reverse complement, a second coding sequence reverse complement, and a second splice acceptor reverse complement, wherein the first coding sequence is operably linked to the first splice acceptor and first terminator, and the second coding sequence is operably linked to the second splice acceptor and second terminator,

wherein the first and second coding sequences differ in nucleic acid sequence but encode the same amino acids, wherein said amino acids encoded by the first and second coding sequences correspond to amino acids encoded by an endogenous gene, and

wherein the transgene is equal to or less than 4.7 kb, and

(ii) adeno-associated virus inverted terminal repeats flanking the transgene, and wherein the recombinant nucleic acid is in a circular conformation.

2. The recombinant nucleic acid of claim 1 , wherein the first terminator is selected from the group consisting of an SV40 poly(A) and a BGH poly(A).

3. The recombinant nucleic acid of claim 2 , wherein the second terminator is selected from the group consisting of an SV40 poly(A) and a BGH poly(A).

4. The recombinant nucleic acid of claim 1 , wherein the transgene does not comprise homology arms.

5. The recombinant nucleic acid of claim 1 , wherein the endogenous gene is selected from the group consisting of Factor VIII, Factor IX, GBA, GLA, IDS, IDUA, ATXN3, USH2A, and G6PT.

6. The recombinant nucleic acid of claim 1 , wherein the endogenous gene encodes alpha-1 antitrypsin.

Continuity (9)
Continuation 17830011 · Jun 1, 2022
Continuation 17590613 · Feb 1, 2022
Continuation 17366290 · Jul 2, 2021
Continuation 16800444 · Feb 25, 2020
Continuation 16601144 · Oct 14, 2019
Provisional Application 62864432 · Jun 20, 2019
Provisional Application 62830654 · Apr 8, 2019
Provisional Application 62746497 · Oct 16, 2018
Related Publication 20240141318A1 · May 2, 2024
Cited By (1)
US 12,441,994